Prometheus Biosciences Announces Appointment of Mark Stenhouse as Chief Operating Officer
News provided by
Share this article
Share this article
SAN DIEGO, March 4, 2021 /PRNewswire/ -- Prometheus Biosciences, Inc. ("Prometheus"), a biotechnology company pioneering a precision medicine approach for the discovery, development, and commercialization of novel therapeutic and companion diagnostic products for the treatment of inflammatory bowel disease (IBD), today announced the appointment of commercial veteran Mark Stenhouse as Chief Operating Officer.
"Mark's leadership and deep experience with GI diagnostics and therapeutics make him a great fit for Chief Operating Officer, which is a key role as we accelerate our growth," said Mark McKenna, President and CEO of Prometheus. "His thirty years of biopharma industry experience, and building and leading successful teams, will strengthen our leadership team as we seek to revolutionize the treatment of IBD with a precision medicine approach for patients with significant unmet medical needs."